Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an
oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for
the induction of remission.